PL375631A1 - Zastosowanie inhibitorów PDE4 i PDE3/4 w leczeniukacheksji - Google Patents

Zastosowanie inhibitorów PDE4 i PDE3/4 w leczeniukacheksji

Info

Publication number
PL375631A1
PL375631A1 PL03375631A PL37563103A PL375631A1 PL 375631 A1 PL375631 A1 PL 375631A1 PL 03375631 A PL03375631 A PL 03375631A PL 37563103 A PL37563103 A PL 37563103A PL 375631 A1 PL375631 A1 PL 375631A1
Authority
PL
Poland
Prior art keywords
pde3
pde4
cachexia
inhibitors
treatment
Prior art date
Application number
PL03375631A
Other languages
English (en)
Inventor
Mathias Schmidt
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of PL375631A1 publication Critical patent/PL375631A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL03375631A 2002-11-27 2003-11-26 Zastosowanie inhibitorów PDE4 i PDE3/4 w leczeniukacheksji PL375631A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02026548 2002-11-27

Publications (1)

Publication Number Publication Date
PL375631A1 true PL375631A1 (pl) 2005-12-12

Family

ID=32338004

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03375631A PL375631A1 (pl) 2002-11-27 2003-11-26 Zastosowanie inhibitorów PDE4 i PDE3/4 w leczeniukacheksji

Country Status (9)

Country Link
US (1) US20060079540A1 (pl)
EP (1) EP1567136A1 (pl)
JP (1) JP2006508996A (pl)
AU (1) AU2003289898A1 (pl)
CA (1) CA2506949A1 (pl)
HR (1) HRP20050572A2 (pl)
IS (1) IS7897A (pl)
PL (1) PL375631A1 (pl)
WO (1) WO2004047817A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
CN102872017B (zh) * 2011-07-13 2015-02-04 中国科学院上海药物研究所 6-(4-(二氟甲氧基)-3-甲氧基苯基)哒嗪-3(2h)-酮在制备抗肿瘤药物中的用途
EP3096749B1 (en) 2014-01-24 2019-05-15 Celgene Corporation Methods for the treatment of obesity using apremilast
US11052085B2 (en) * 2017-11-28 2021-07-06 University Of Cincinnati Methods for treating skeletal muscle cachexia arising from burn injury by administering PDE4B-selective inhibitors
US12582809B2 (en) 2018-01-26 2026-03-24 Bt Bidco, Inc. Treatment of a disease of the gastrointestinal tract with a PDE4 inhibitor
US20240252795A1 (en) 2018-11-19 2024-08-01 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN109908139B (zh) * 2018-12-28 2022-02-22 南京市儿童医院 西洛司特在制备用于治疗急性肾损伤相关病症的药物中的用途
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
WO2024168096A2 (en) * 2023-02-07 2024-08-15 Biotheryx, Inc. Pde4 degraders, pharmaceutical compositions, and therapeutic applications

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL100088A (en) * 1990-11-21 1995-07-31 Smithkline Beecham Corp FNT inhibitor preparations containing histogenic transducts converted at positions 1, 3, and 8
US5728844A (en) * 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
US6131156A (en) * 1996-05-31 2000-10-10 Hewlett-Packard Company Optimized storage system and method for a processor that executes instructions out of order
CZ20001623A3 (cs) * 1997-11-04 2001-08-15 Pfizer Products Inc. Terapeuticky účinné látky na bázi nahrazení katecholu indazolovým bioisosterem v inhibitorech PDE4
AP2001002068A0 (en) * 1998-08-11 2001-03-31 Pfizer Prod Inc Substituted 1,8-naphthyridin-4(1H)-ones as phosphodiesterase 4 inhibitors.
US6180650B1 (en) * 1999-04-23 2001-01-30 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE 4 inhibitors
US6313156B1 (en) * 1999-12-23 2001-11-06 Icos Corporation Thiazole compounds as cyclic-AMP-specific phosphodiesterase inhibitors
US6294561B1 (en) * 1999-12-23 2001-09-25 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
NZ519547A (en) * 2000-01-31 2004-03-26 Pfizer Prod Inc Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of PDE4 isozymes
US6639077B2 (en) * 2000-03-23 2003-10-28 Merck Frosst Canada & Co. Tri-aryl-substituted-ethane PDE4 inhibitors
WO2001097749A2 (en) * 2000-06-23 2001-12-27 Kotze, Gavin, Salomon The use of synthetic, non-hormonal 21-aminosteroids and thereof
US6670334B2 (en) * 2001-01-05 2003-12-30 University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
ES2239203T3 (es) * 2001-01-31 2005-09-16 Pfizer Products Inc. Derivados nicotinamida y sus mimeticos como inhibidores de isozimas pde4.
WO2002060898A1 (en) * 2001-01-31 2002-08-08 Pfizer Products Inc. Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of pde4 isozymes

Also Published As

Publication number Publication date
WO2004047817A1 (en) 2004-06-10
JP2006508996A (ja) 2006-03-16
HRP20050572A2 (en) 2006-08-31
IS7897A (is) 2005-06-20
US20060079540A1 (en) 2006-04-13
CA2506949A1 (en) 2004-06-10
AU2003289898A1 (en) 2004-06-18
EP1567136A1 (en) 2005-08-31

Similar Documents

Publication Publication Date Title
PL372395A1 (pl) Zastosowanie inhibitorów cyklooksygenazy i środków antymuskarynowych do leczenia nietrzymania moczu
EP1549614A4 (en) VASCULATORY AGENTS AND METHODS FOR THEIR APPLICATION
IL161258A0 (en) Heterocyclic compounds and methods of use
AU2003217870A8 (en) Pini-modulating compounds and methods of use thereof
AU2002324775A8 (en) Architecture tool and methods of use
AU2003213673A8 (en) Pin1-modulating compounds and methods of use thereof
AU2003223579A8 (en) Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease
PL374598A1 (pl) Inhibitory kaspazy i ich zastosowania
ZA200501381B (en) New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
AU2002259130A1 (en) Agents for treatment of hcv and methods of use
EP1515725A4 (en) USE OF CYCLOTHIOCARBAMATE DERIVATIVES IN THE TREATMENT OF HORMONE-RELATED ILLNESSES
HUP0400005A3 (en) Use of osteopontin for the treatment and/or prevention of neurologic diseases
ZA200410409B (en) Use of thio-oxindole derivatives in treatment of hormonerelated conditions
ZA200208228B (en) Use of il-18 inhibitors for the treatment and/or prevention of athesclerosis
AU2003232848A8 (en) Phenylaminopyrimidines and their use as rho-kinase inhibitors
PL375631A1 (pl) Zastosowanie inhibitorów PDE4 i PDE3/4 w leczeniukacheksji
AU5754701A (en) Method of using cox-2 inhibitors in the treatment and prevention of ocular cox-2mediated disorders
AU2002241661A1 (en) Multifunctional protease inhibitors and their use in treatment of disease
AU2003210983A8 (en) Kinase inhibitors and methods of use thereof
AU2002337913A1 (en) Glycosulfopeptide inhibitors and methods of use thereof
PL361733A1 (pl) Sulfamidotienopirymidyny
PL377617A1 (pl) Retraktor prowadzony i sposoby stosowania
HUP0303342A3 (en) Carbamate compounds for use in preventing and treating psychotic disorders
AU3270301A (en) Combined pde3 and pde4 inhibitor therapy for the treatment of obesity
PL363544A1 (pl) Nowe pochodne piperazynowe

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)